These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22003308)

  • 21. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
    J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
    Manzoni P; Baraldi E; Luna MS; Tzialla C
    Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland.
    Thwaites R; Buchan S; Fullarton J; Morris C; Grubb E; Rodgers-Gray B; Coutts J
    Eur J Pediatr; 2020 May; 179(5):791-799. PubMed ID: 31912234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
    Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
    Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY; Saleem M; Paes BA; Mitchell I; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
    Makari D; Checchia PA; Devincenzo J
    Hum Vaccin Immunother; 2014; 10(3):607-14. PubMed ID: 24316863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.
    Bennett MV; McLaurin K; Ambrose C; Lee HC
    PLoS One; 2018; 13(10):e0205399. PubMed ID: 30379957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.
    Goldstein M; Fergie J; Krilov LR
    Infect Dis Ther; 2021 Mar; 10(Suppl 1):17-26. PubMed ID: 33656649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
    Lin YJ; Chung CH; Chi H; Lin CH
    Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.
    Figueras-Aloy J; Manzoni P; Paes B; Simões EA; Bont L; Checchia PA; Fauroux B; Carbonell-Estrany X
    Infect Dis Ther; 2016 Dec; 5(4):417-452. PubMed ID: 27628014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity and Cost of RSV Hospitalization Among US Preterm Infants Following the 2014 American Academy of Pediatrics Policy Change.
    Krilov LR; Forbes ML; Goldstein M; Wadhawan R; Stewart DL
    Infect Dis Ther; 2021 Mar; 10(Suppl 1):27-34. PubMed ID: 33656650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study.
    Sheridan-Pereira M; Murphy J; Sloan J; Crispino G; Leahy A; Corcoran JD; Dempsey E; Elnazir B; Gavin P; Sharif F; Gul R; Satas S; Murphy J; Gormally S; Shanaa I; Waldron D; Mc Mahon P; Carson J; Blanken M; Bont L; Paes B
    Pediatr Infect Dis J; 2016 Jan; 35(1):19-24. PubMed ID: 26379160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.